Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16260639rdf:typepubmed:Citationlld:pubmed
pubmed-article:16260639lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C0000854lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C0070166lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C0205253lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C1707391lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C2348535lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C0595454lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C1708715lld:lifeskim
pubmed-article:16260639lifeskim:mentionsumls-concept:C2346689lld:lifeskim
pubmed-article:16260639pubmed:issue19lld:pubmed
pubmed-article:16260639pubmed:dateCreated2005-11-8lld:pubmed
pubmed-article:16260639pubmed:abstractTextFor patients undergoing percutaneous coronary intervention, the administration of a clopidogrel loading dose ranging from 300 to 600 mg is currently recommended. It is unknown, though, whether loading doses higher than 600 mg exert additional suppression of platelet function.lld:pubmed
pubmed-article:16260639pubmed:languageenglld:pubmed
pubmed-article:16260639pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16260639pubmed:citationSubsetAIMlld:pubmed
pubmed-article:16260639pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16260639pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16260639pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16260639pubmed:statusMEDLINElld:pubmed
pubmed-article:16260639pubmed:monthNovlld:pubmed
pubmed-article:16260639pubmed:issn1524-4539lld:pubmed
pubmed-article:16260639pubmed:authorpubmed-author:KastratiAdnan...lld:pubmed
pubmed-article:16260639pubmed:authorpubmed-author:SchömigAlbert...lld:pubmed
pubmed-article:16260639pubmed:authorpubmed-author:SchömigEdgarElld:pubmed
pubmed-article:16260639pubmed:authorpubmed-author:von...lld:pubmed
pubmed-article:16260639pubmed:authorpubmed-author:TaubertDirkDlld:pubmed
pubmed-article:16260639pubmed:authorpubmed-author:Pogatsa-Murra...lld:pubmed
pubmed-article:16260639pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16260639pubmed:day8lld:pubmed
pubmed-article:16260639pubmed:volume112lld:pubmed
pubmed-article:16260639pubmed:ownerNLMlld:pubmed
pubmed-article:16260639pubmed:authorsCompleteYlld:pubmed
pubmed-article:16260639pubmed:pagination2946-50lld:pubmed
pubmed-article:16260639pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:meshHeadingpubmed-meshheading:16260639...lld:pubmed
pubmed-article:16260639pubmed:year2005lld:pubmed
pubmed-article:16260639pubmed:articleTitleAbsorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.lld:pubmed
pubmed-article:16260639pubmed:affiliationDeutsches Herzzentrum, Technische Universität München, Munich, Germany. beckerath@dhn.mhn.delld:pubmed
pubmed-article:16260639pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16260639pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16260639pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:16260639pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16260639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16260639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16260639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16260639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16260639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16260639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16260639lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16260639lld:pubmed